DAVION HEALTHCARE PLC
Davion Healthcare develops non-invasive home tests for early detection, prevention and monitoring of health anomalies. Headquartered in Ireland, it maintains an operation in Cyprus through its wholly owned subsidiary. Its products are designed for direct over-the-counter consumer use, subject to applicable regulatory requirements. BreastCheck and FootFlow use thermochromic liquid crystal film to map skin-temperature differences; BreastCheck is intended to provide an early-stage guide to possible breast abnormalities, while FootFlow compares foot temperatures as an early-stage guide for clinicians regarding circulation-related conditions. The portfolio also includes Testic and ThermaDerm. Davion uses third-party research and development, outsourced manufacturing and design, and a licensing-based commercialization model. It licenses manufacturing, marketing, sales and distribution rights to regional or global partners, which generally handle regulatory requirements, production and customer support. Davion typically earns upfront or periodic licensing fees and ongoing royalties based on sales or units. It has a global manufacturing and distribution license agreement with NeuRX Health, Inc. for BreastCheck.
No SEC Form 4 filings for $DAVI in the last 30 days.
See all $DAVI insider activity →Davion Healthcare (DAVI) appointed Vienna Capital Partners to advise on a $100M acquisition financing target for 2027, with potential for increase. No binding commitments secured yet. This follows a recent $13.5M acquisition announcement.
Davion Healthcare (DAVI) agreed to acquire Healthcare Stat Homecare (HSH) for $13.5M, including $8M cash and $5.5M in shares. HSH reported $11.6M gross receipts and $1.9M income in 2025. DAVI stock is down 8.77% to $3.00.
Davion Healthcare Plc (DAVI) acquired Humaskan Medical IP for $25M, including $2.5M cash and 1,730,770 shares at $13.00. The deal involves WoundSkan and Spektra technologies, with shares subject to a 90-day deferral and sales restrictions. This is Davion's first acquisition since its Nasdaq direct listing.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning DAVI (DAVION HEALTHCARE PLC). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent DAVI coverage spans corporate actions and mergers & acquisitions.
The financing target could enable future acquisitions, supporting growth expectations.
Deal announcement should be viewed as modestly dilutive or neutral near term, with upside tied to integrating an established home-health operator.
The acquisition adds new product assets and potential revenue streams but introduces dilution.
New listing likely drives initial buying interest and volatility.
AlphAI scores every news story that mentions DAVI with an AI model for sentiment and relevance, and aggregates insider trades from DAVION HEALTHCARE PLC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Davion Healthcare (DAVI) appointed Vienna Capital Partners to advise on a $100M acquisition financing target for 2027, with potential for increase. No binding commitments secured yet. This follows a recent $13.5M acquisition announcement.
Davion Healthcare (DAVI) agreed to acquire Healthcare Stat Homecare (HSH) for $13.5M, including $8M cash and $5.5M in shares. HSH reported $11.6M gross receipts and $1.9M income in 2025. DAVI stock is down 8.77% to $3.00.
Davion Healthcare Plc (DAVI) acquired Humaskan Medical IP for $25M, including $2.5M cash and 1,730,770 shares at $13.00. The deal involves WoundSkan and Spektra technologies, with shares subject to a 90-day deferral and sales restrictions. This is Davion's first acquisition since its Nasdaq direct listing.
Davion Healthcare Plc, a digital healthcare company, will begin trading on Nasdaq under ticker 'DAVI' on October 22, 2026. Its flagship product, BreastCheck, is an at-home breast health screening test. The company plans to grow through commercialization and acquisitions, with new leadership appointed. Davion also develops other health monitoring technologies, such as FootFlow and Testic.
